Company Overview
Snapshot
Founded in November 2022, AlgaVac operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing its microalgae-based oral vaccine platform for aquaculture.
Business overview
AlgaVac is an aquaculture biotechnology company specializing in an algae-based oral delivery platform for vaccines and disease treatments in fish and other aquaculture species. The company utilizes genetically transformed microalgae to create an algal powder that can be integrated into feed, enabling vaccine delivery through regular feeding rather than traditional injection methods. This approach aims to reduce reliance on manual injectable vaccination, plastic medical consumables, and handling-intensive disease prevention in the aquaculture industry. AlgaVac operates within the Health Tech & Life Sciences sector, specifically targeting Pharma & Medical Biotechnology and Drugs Discovery & Development.
Log in to access full profile ›Company Intelligence Q&A
- What is AlgaVac's core technology?
- AlgaVac utilizes genetically transformed microalgae as a cell-based production and bio-encapsulation system to create an algal powder for oral vaccine delivery in aquaculture.
- What problem does AlgaVac aim to solve in aquaculture?
- AlgaVac aims to reduce the reliance on manual injectable vaccination, plastic medical consumables, and handling-intensive disease prevention methods in aquaculture by offering an oral vaccine delivery system.
- When was AlgaVac founded?
- AlgaVac was founded in November 2022.
- What is AlgaVac's current product development stage?
- AlgaVac's products are currently in the Research & Development (R&D) stage, focusing on developing microalgae-based oral vaccines for aquaculture.
- Has AlgaVac established any notable collaborations?
- AlgaVac has reported proof-of-concept collaborations with Virbac, Temasek Polytechnic, and Israel’s Agricultural Research Organization for oral fish vaccine and growth-promoting applications.